Abstract: Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract.

Abstract: The invention relates to a method for the in vitro detection and/or differentiation and/or progress observation of pathophysiological conditions with the aid of sample nucleic acids, including determination of gene activities by means of a plurality of polynucleotides, determination of gene activities of at least one internal reference gene, and formation of an index value from the single determined normalized gene activities of a multigene biomarker indicating the pathophysiological condition.

Abstract: The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, the protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.

Abstract: The present invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure.

Abstract: The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.

Abstract: A method is described for enriching procaryotic DNA, said method including the steps of contacting at least one procaryotic DNA with at least one protein or polypeptide which is capable of specifically binding to non-methylated CpG motifs, and separating the protein/polypeptide-DNA complex. Moreover, the application relates to a kit for carrying out said method.

Abstract: The present invention relates to the use of gene activity markers for classification of patients suffering from infectious and non-infectious multiple organ failure, respectively. The present invention in particular relates to gene activity markers for classification of patients as “not infected without multiple organ failure” or as “not suffering from infectious multiple organ failure” or as “suffering from infectious multiple organ failure”, the gene activity markers being polynucleotides selected from the group consisting of: SEQ ID I.1, SEQ ID I.2, SEQ ID I.3, SEQ ID I.4, SEQ ID I.5, SEQ ID I.6, SEQ ID I.7, SEQ ID I.8 and SEQ ID I.9 or partial sequences thereof.

Abstract: A method is described for enriching procaryotic DNA, said method including the steps of contacting at least one procaryotic DNA with at least one protein or polypeptide which is capable of specifically binding to non-methylated CpG motifs, and separating the protein/polypeptide-DNA complex. Moreover, the application relates to a kit for carrying out said method.

Abstract: A method is described for enriching procaryotic DNA, said method including the steps of contacting at least one procaryotic DNA with at least one protein or polypeptide which is capable of specifically binding to non-methylated CpG motifs, and separating the protein/polypeptide-DNA complex. Moreover, the application relates to a kit for carrying out said method.

Abstract: The invention relates to a method for the in vitro detection and/or differentiation and/or progress observation of pathophysiological conditions with the aid of sample nucleic acids, including determination of gene activities by means of a plurality of polynucleotides, determination of gene activities of at least one internal reference gene, and formation of an index value from the single determined normalized gene activities of a multigene biomarker indicating the pathophysiological condition.

Abstract: The present invention relates to methods and means for determining pathogenic fungi in a sample material, e.g. blood. In the method, the bacterial DNA is initially enriched from the total DNA of the sample material, and then the enriched DNA is amplified with specific primer pairs. Detection of the obtained amplicons allows the accurate identification of bacteria and fungi contained in the sample material and of their resistances. The methods and means of the invention allow an early diagnosis of inflammatory diseases, in particular involving non-detected infection (SIRS), and of infectious diseases such as sepsis, spontaneous bacterial peritonitis and endocarditis.

Abstract: The present invention concerns the use of polynucleotides having a length of 2 to 100% of the number of nucleotides of the single sequences according to SEQ ID No. 1 to SEQ ID No. 69 and/or their gene loci and/or their transcripts for detecting gene activities for the differentiation of a condition accompanying a local infection from a condition accompanying a systemic infection of a patient, wherein all of the sequences according to SEQ ID No. 1 to SEQ ID No. 69 are used; as well as a method and a kit for performing the method.

Abstract: The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.

Abstract: The present invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for detecting any postoperative tissue incompatibility reactions following a liver transplantation, wherein in patients the gene activity of a plurality of specific genes relevant to a liver transplantation is determined in a patient sample, and the specific genes and/or gene fragments for monitoring of postoperative states are selected from the group consisting of: SEQ-ID No. 1 to SEQ-ID No. 532, these preferably being subdivided into several clusters.

Abstract: The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients.

Abstract: Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract.

Abstract: The present invention relates to the use of gene activity markers for classification of patients suffering from infectious and non-infectious multiple organ failure, respectively. The present invention in particular relates to gene activity markers for classification of patients as “not infected without multiple organ failure” or as “not suffering from infectious multiple organ failure” or as “suffering from infectious multiple organ failure”, the gene activity markers being polynucleotides selected from the group consisting of: SEQ ID 1.1, SEQ ID 1.2, SEQ ID 1.3, SEQ ID 1.4, SEQ ID 1.5, SEQ ID 1.6, SEQ ID 1.7, SEQ ID 1.8 and SEQ ID 1.9 or partial sequences thereof.

Abstract: The present invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure.

Abstract: The invention relates to a method for the in vitro discrimination between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions.

Abstract: The present invention relates to a method for in vitro detection of SIRS, sepsis and/or sepsis-like conditions. This method renders the evaluation of the severity and/or the therapeutic progress of sepsis and severe infections, in particular sepsis-like systemic infections possible. Further, the present invention relates to the use of recombinantly or synthetically prepared nucleic acid sequences or peptide sequences derived therefrom as calibrator in sepsis assays and/or for the evaluation of the effect and the toxicity during screening of the active agents and/or the preparation of therapeutics for the prevention and treatment of SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.